在EGFR变异的非小细胞肺癌中使用Ivonescimab加化学疗法:随机临床试验
, Wenfeng Fang1, Yuanyuan Zhao1
1Sun Yat-sen University Cancer Center, Guangzhou, China.
JAMA
|May 31, 2024
概括
在以前接受EGFR氨酸激酶抑制剂 (EGFR- TKIs) 治疗的非小细胞肺癌患者中,Ivonescimab与化疗相结合显著改善了无进展生存率. 这种组合治疗显示出可容忍的安全性,为复发或转移性疾病提供了新的选择.
科学领域:
- 癌症学
- 医学研究
- 临床试验
背景情况:
- 非小细胞肺癌 (NSCLC) 患者在表皮生长因子受体氨酸激酶抑制剂 (EGFR- TKI) 治疗中进展,特别是第三代TKI患者的最佳治疗选择有限.
- 具有EGFR变异的复发性或转移性NSCLC具有重大临床挑战,需要新的治疗策略.
研究的目的:
- 在患有复发性晚期或转移性NSCLC的EGFR变异患者中,评估IVONESCIMAB与化疗结合的疗效和安全性.
- 确定IVONESCIMAB加化疗是否能改善该患者群体的无进展生存期 (PFS).
主要方法:
- 在中国55个地区进行了一项双盲,安慰剂对照,随机的第三期试验.
- 总共有322名符合条件的患者被录取并随机分配给接受IVONESCIMAB或安慰剂,两者与佩米雷克斯德和卡博普拉丁联合使用,随后进行维持治疗.
主要成果:
- 与安慰剂组相比,IVONESCIMAB组的无进展生存时间 (PFS) 中位数显著长 (7. 1个月),危险率为0. 46 (P < . 001).
- 在各个子组中观察到PFS的好处,包括患有第三代EGFR- TKI和脑转移的患者.
- 与安慰剂组相比,IVONESCIMAB组的客观反应率更高 (50. 6%).
- 与安慰剂组相比,IVONESCIMAB组的3级或更高的治疗不良事件更为频繁 (61.5%),大多数与化疗相关.
结论:
- 在TKI治疗的NSCLC患者中,Ivonescimab加化学疗法显著改善了PFS的可控安全性.
- 在EGFR-TKI治疗中进展的晚期或转移性NSCLC患者中,这种组合治疗是一种有前途的新疗法.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
